Biocon arm inks pact for clinical research with US firm

Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
Real-time Stock quotes, portfolio, LIVE TV and more.
GeStepAhead SME Special
moneycontrol.com

Home » News » Business

Aug 22, 2011, 07.39 PM | Source: PTI

Biocon arm inks pact for clinical research with US firm

Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.

Like this story, share it with millions of investors on M3

Biocon arm inks pact for clinical research with US firm

Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.

Post Your Comments

Share Cancel

Biocon arm inks pact for clinical research with US firm
Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.

This partnership establishes a cost-efficient global footprint for clinical pharmacology services, providing an opportunity for both organisations to engage pharmaceutical clients strategically, Biocon said in a statement.

Clinigene Chief Operating Officer Abhijit Barve said: "Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development, streamlining processes while maintaining high quality.

"Our strategic partnership is designed to deliver this in a very cost-effective manner."

The company, however, did not disclose financial details.

"With Clinigene's expertise and cost-effective approach... Our clients are able to easily structure a program for their compound that delivers high-value value," Spaulding Clinical CEO Randol Spaulding said.

Shares of Biocon today closed at Rs 329.20 on the Bombay Stock Exchange, up 2.01% from its previous close.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Biocon arm inks pact for clinical research with US firm

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login